M. Farinas

Plasma biomarkers and incident clinical stage progression in the specialized memory clinic: a longitudinal study

INTRODUCTION: The utility of blood-based Alzheimer's disease (AD) biomarkers in predicting clinical trajectories remains uncertain. METHODS: We assessed the diagnostic and prognostic performance of p-tau181, p-tau217, GFAP, and NfL in a large memory-clinic cohort (n=3,645) with comprehensive baseline clinical evaluatio...

A-93: Predictive Value of Plasma ADRD Biomarkers in Cognitive Responsiveness to Lifestyle Modification Intervention in Older Adults With Remitted Late-life Depression

Objective: Late-life depression (LLD) increases dementia risk, emphasizing the potential and importance of lifestyle interventions to support cognition. However, no biomarker-based models currently exist to predict their effectiveness. We examined whether plasma Alzheimer’s disease and related dementia (ADRD) biomark...

Plasma eMTBR-tau as a robust biomarker for Alzheimer's disease tangle pathology up to 10 years before death

Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer's disease prognosis, diagnosis and monitoring. Here, we show that a blood-based immunoassay for an endogenously-cleaved eMTBR-tau fragment of tau protein is strongly associated with autopsy-diagnosed Alzheimer neuropathologi...

Association between plasma brain-derived p-tau variants and anxiety phenotypes in older adults

Clinical utility of plasma APOE proteotyping for Alzheimer's disease risk and prognosis

Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder strongly influenced by genetic factors, with apolipoprotein E (APOE) {epsilon}4 allele being the most established risk variant. Although DNA-based genotyping remains standard, plasma proteotyping may provide scalable, isoform-specific alternat...

Analytical performance of a delayed-centrifugation blood collection tube for remote blood biomarker assessment

Current biobanking guidelines require in-person blood collection and immediate processing for Alzheimer's disease (AD) biomarker assessment. We recently reported that the P100 blood collection tubes containing protease inhibitors improve protein biomarker stability over delayed centrifugation periods. However, whether...

Association of age with clinical progression across plasma p-tau217 levels

These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment and support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.

Proteomic markers linking anxiety phenotypes to Alzheimers disease risk: a multi-analyte proteomic analysis

Distinct anxiety phenotypes map onto dissociable plasma proteomic profiling, converging on a shared neurodegeneration axis reflecting neuronal injury, while diverging across neuroimmune, vascular, and proteostatic domains.